NIH sickle cell partner AesRx moves up the food chain in Baxter buyout
Having played a pioneering role collaborating with the NIH on a new drug for sickle cell disease, Newton, MA-based AesRx has moved up the food chain after completing a buyout deal with Baxter International.
Baxter's latest bleeding drug hits the mark in PhIII
Baxter charted another late-stage success in its growing hemophilia franchise, posting positive top-line results for an orphan bleeding disorder treatment.
UPDATED: Biogen's Alprolix nod is just the first tremor in a hemophilia market shake-up
New, long-acting hemophilia therapies are preparing to take the market by storm. For patients, they'll require less frequent infusions, proving more convenient. But for current market leaders like Baxter International, they could put millions in jeopardy as they take hold of the global markets for hemophilia A and B, worth a combined $7 billion.
The same day Baxter announced it would be dividing into separate biopharma and med tech companies come 2015, it revealed plans to sell its vaccines unit as part of the larger breakup.
Baxter plans to divide itself into two separate companies
Baxter International plans to split itself into two separate companies, one focused on medical products and the other centered on biopharmaceuticals.
Baxter to spin off its $6B biopharma business in industry's latest split-up
The pharma split-up movement is spreading. Baxter International says it will spin off its biopharma business into a separate company, leaving its $9 billion medical products business to venture on under the Baxter name.
Baxter is looking into selling its vaccine business, Reuters reports. The process is at an early stage, with Baxter having recently tapped Goldman Sachs to advise and begun contacting potential buyers, including private equity firms.
Baxter scrambles to retrieve glucose bags after reports of patient reactions
When Baxter International issued product recalls in December and January, it said there had been no reports of adverse events. But Baxter couldn't make that claim Wednesday when the company recalled a single lot of a dialysis product in which mold was found.
FDA publishes its warning letter to Baxter over home dialysis and infusion devices
A Baxter Healthcare plant in Illinois failed to put in place adequate quality control practices in the manufacture of HomeChoice dialysis and iPump pain management systems, the FDA tells the company in a warning letter.
Baxter nails a CE mark for next-generation home hemodialysis
Baxter International made a splash in 2013 with its nearly $4 billion acquisition of Swedish dialysis competitor Gambro. It ends the year with a quieter accomplishment: a CE mark in Europe for a next-generation home dialysis device.